EW Q4 2022 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q4 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.3B+1.4% YoY

Gross Profit

$1.1B78.1% margin

Operating Income

$410M30.4% margin

Net Income

$398M29.5% margin

EPS (Diluted)

$0.65

QoQ Revenue Growth

+2.2%

Cash Flow

Operating Cash Flow

$283M

Free Cash Flow

$194M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$8.3B

Total Liabilities

$2.5B

Stockholders' Equity

$5.8B

Cash & Equivalents

$769M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.3B	$1.3B	+1.4%
Gross Profit	$1.1B	$1.0B	+3.3%
Operating Income	$410M	$362M	+13.2%
Net Income	$398M	$335M	+18.8%

Revenue Segments

Transcatheter Heart Valves

$868M64%

Critical Care

$225M17%

Surgical Heart Valve Therapy

$224M17%

Transcatheter Mitral And Tricuspid Therapies

$32M2%

Geographic Segments

UNITED STATES

$796M59%

Europe

$291M22%

Rest of World

$151M11%

JAPAN

$111M8%